Language

English

Publication Date

5-21-2024

Journal

Cell Reports Medicine: Cell Press

DOI

10.1016/j.xcrm.2024.101547

PMID

38703764

PMCID

PMC11148773

PubMedCentral® Posted Date

5-3-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Non-clear cell renal cell carcinomas (non-ccRCCs) encompass diverse malignant and benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis of aggressive disease, and therapeutic targets to complement immunotherapy are current clinical needs. Multi-omics analyses of 48 non-ccRCCs compared with 103 ccRCCs reveal proteogenomic, phosphorylation, glycosylation, and metabolic aberrations in RCC subtypes. RCCs with high genome instability display overexpression of IGF2BP3 and PYCR1. Integration of single-cell and bulk transcriptome data predicts diverse cell-of-origin and clarifies RCC subtype-specific proteogenomic signatures. Expression of biomarkers MAPRE3, ADGRF5, and GPNMB differentiates renal oncocytoma from chromophobe RCC, and PIGR and SOSTDC1 distinguish papillary RCC from MTSCC. This study expands our knowledge of proteogenomic signatures, biomarkers, and potential therapeutic targets in non-ccRCC.

Keywords

Humans, Proteogenomics, Kidney Neoplasms, Biomarkers, Tumor, Carcinoma, Renal Cell, Transcriptome, Male, Female, Middle Aged, Gene Expression Regulation, Neoplastic, non-clear cell renal cell carcinoma, weighted genome instability index, cell-of-origin, proteogenomics, differential diagnosis biomarkers, prognostic marker, metabolomics, CPTAC, phosphoproteomics, glycoproteomics

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.